# Rapport Therapeutics Shares Close 2.7% Higher on Phase 2 Results Day By John Kim Canonical URL: https://www.tokenpost.com/news/business/36102 Published: 2026-10-20T23:26:08.000Z Updated: 2026-10-20T23:26:08.000Z Section: Business > Monday’s 3.74% gain came before the announcement. RAP-219 met the primary and secondary endpoints in a three-week trial. Rapport Therapeutics (RAPP) shares closed Tuesday at $29.37, up 2.7% from Monday, the day before the company announced topline Phase 2 results for its experimental drug RAP-219 in adults with acute mania associated with bipolar I disorder. The Tuesday close was recorded at 4 p.m. ET (20:00 UTC). Monday’s $28.60 close was 3.74% above the previous session’s $27.57 close. That gain preceded the trial announcement. The three-week trial enrolled 253 U.S. adults experiencing acute mania linked to bipolar I disorder. It used a randomized, double-blind, placebo-controlled design, with patients treated in an inpatient setting. The topline findings showed RAP-219 met the study’s primary and secondary endpoints. At Week 3, mean scores on the Young Mania Rating Scale (YMRS), a clinician-administered measure of manic symptoms, had fallen 15.4 points from baseline for patients taking RAP-219, compared with 12.3 points for those taking placebo. The 3.1-point difference versus placebo was the result on the primary endpoint (p=0.045). On a secondary measure of mania severity, the difference versus placebo was 0.4 point (p=0.024). Treatment-emergent adverse events occurred in 51.6% of patients receiving RAP-219 and 52.8% of those receiving placebo. All reported events were mild or moderate. Adverse events led 3.2% of patients in the RAP-219 group and 0.8% in the placebo group to stop treatment. The figures are topline results from a mid-stage study. Rapport plans to present more trial data, including safety follow-up covering the eight weeks after treatment, at a future medical meeting. TokenPost previously covered [RAP-219’s Phase 2 trial results](). Rapport plans to discuss the results and a registrational trial design with the U.S. Food and Drug Administration in the first quarter of 2027. The company expects to begin two Phase 3 trials in the second half of 2027. ## Links in this article - [RAP-219’s Phase 2 trial results](https://www.tokenpost.com/news/business/35833)